Product

REM0046127

Aliases

350mg oral suspension, REM0046127 Low Dose

1 clinical trial

1 indication

Indication

Alzheimer's disease

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease

Status: Recruiting, Estimated PCD: 2024-06-07